Breast cancer early detection and diagnostic capacity in Uganda.


Journal

Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236

Informations de publication

Date de publication:
15 05 2020
Historique:
received: 24 01 2020
revised: 24 02 2020
accepted: 25 02 2020
entrez: 30 4 2020
pubmed: 30 4 2020
medline: 22 5 2021
Statut: ppublish

Résumé

Greater than 80% of women presenting for breast cancer treatment in Uganda have late-stage disease, which is attributable to a dysfunctional referral system and a lack of recognition of the early signs and symptoms among primary health care providers, and compounded by the poor infrastructure and inadequate human capacity. Improving the breast health care system requires a systemic approach beginning with situational analysis to identify systematic gaps that prevent sustainable improvements in outcome. The authors performed a situational analysis of the breast health care system using methods developed by the Breast Health Global Initiative. Based on their findings, they developed a series of recommendations for strengthening the health system for the early diagnosis of breast cancer based on clinical detection, referral, tissue sampling, and diagnosis. Deficits in the recognition of breast cancer signs and symptoms, the underuse of clinical breast examination as a diagnostic and/or screening tool, the centralization of diagnostic tests (radiology and pathology), reliance on excisional biopsies rather than needle biopsies, and a lack of trained professionals and knowledge of the referral system all contribute to significant health system delays. To strengthen referral networks and improve the early diagnosis of breast cancer in Uganda, national referral hospitals should provide educational programs to primary health care providers in community health centers (CHCs), at which the majority of women first present with symptoms. At secondary district-level facilities in which imaging and tissue sampling can be performed, the capacity for diagnostic testing could be increased through task shifting of basic interpretation (abnormal vs normal) from specialists to nonspecialists using networking technology to facilitate remote oversight from specialists at the national referral hospitals.

Sections du résumé

BACKGROUND
Greater than 80% of women presenting for breast cancer treatment in Uganda have late-stage disease, which is attributable to a dysfunctional referral system and a lack of recognition of the early signs and symptoms among primary health care providers, and compounded by the poor infrastructure and inadequate human capacity. Improving the breast health care system requires a systemic approach beginning with situational analysis to identify systematic gaps that prevent sustainable improvements in outcome.
METHODS
The authors performed a situational analysis of the breast health care system using methods developed by the Breast Health Global Initiative. Based on their findings, they developed a series of recommendations for strengthening the health system for the early diagnosis of breast cancer based on clinical detection, referral, tissue sampling, and diagnosis.
RESULTS
Deficits in the recognition of breast cancer signs and symptoms, the underuse of clinical breast examination as a diagnostic and/or screening tool, the centralization of diagnostic tests (radiology and pathology), reliance on excisional biopsies rather than needle biopsies, and a lack of trained professionals and knowledge of the referral system all contribute to significant health system delays.
CONCLUSIONS
To strengthen referral networks and improve the early diagnosis of breast cancer in Uganda, national referral hospitals should provide educational programs to primary health care providers in community health centers (CHCs), at which the majority of women first present with symptoms. At secondary district-level facilities in which imaging and tissue sampling can be performed, the capacity for diagnostic testing could be increased through task shifting of basic interpretation (abnormal vs normal) from specialists to nonspecialists using networking technology to facilitate remote oversight from specialists at the national referral hospitals.

Identifiants

pubmed: 32348563
doi: 10.1002/cncr.32890
pmc: PMC7219536
mid: NIHMS1584213
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2469-2480

Subventions

Organisme : Radiological Society of North America
Organisme : Susan G. Komen
ID : SAC170082
Pays : United States
Organisme : National Comprehensive Cancer Network
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : Novartis
Organisme : NCI NIH HHS
ID : 1R13CA224776-01A1
Pays : United States
Organisme : American Society of Clinical Oncology
Organisme : General Electric
Organisme : pH Trust
Organisme : Journal of Global Oncology
Organisme : Pfizer
Organisme : Union for International Cancer Control
Organisme : American Society of Clinical Pathology
Organisme : NCI NIH HHS
ID : R13 CA224776
Pays : United States
Organisme : Seattle Cancer Care Alliance
Organisme : Cepheid
Organisme : University of Washington
Organisme : GE Healthcare
Organisme : UE LifeSciences
Organisme : Fred Hutchinson Cancer Research Center
Organisme : National Breast Cancer Foundation
Organisme : Susan G. Komen
ID : GSP18BHGI001
Pays : United States

Informations de copyright

© 2020 American Cancer Society.

Références

Acad Radiol. 2016 Oct;23(10):1271-7
pubmed: 27325412
Psychooncology. 2016 Oct;25(10):1206-1211
pubmed: 27421234
PLoS One. 2016 Jan 29;11(1):e0148672
pubmed: 26824770
World J Surg Oncol. 2015 Jul 19;13:220
pubmed: 26187151
PLoS One. 2014 Jan 08;9(1):e84945
pubmed: 24416316
J Glob Oncol. 2018 Sep;4:1-9
pubmed: 30241166
AJR Am J Roentgenol. 2000 Sep;175(3):779-87
pubmed: 10954467
Cancer. 2008 Oct 15;113(8 Suppl):2244-56
pubmed: 18837017
J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389
pubmed: 30442736
BMC Pediatr. 2015 Aug 28;15:103
pubmed: 26315284
J Natl Compr Canc Netw. 2018 May;16(5S):628-631
pubmed: 29784742
Lancet Oncol. 2015 Mar;16(3):e137-47
pubmed: 25752564
J Glob Oncol. 2017 Apr;3(2):105-113
pubmed: 28503660
Br J Cancer. 2008 Jul 8;99(1):63-7
pubmed: 18577991
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncologist. 2019 May;24(5):624-631
pubmed: 30072390
Breast J. 2003 May-Jun;9 Suppl 2:S81-5
pubmed: 12713501
J Am Coll Radiol. 2016 Feb;13(2):163-9
pubmed: 26419306

Auteurs

John R Scheel (JR)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington.
Department of Global Health, University of Washington, Seattle, Washington.

Mahbod J Giglou (MJ)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Sophie Segel (S)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Jackson Orem (J)

Uganda Cancer Institute, Kampala, Uganda.

Vivien Tsu (V)

Department of Global Health, University of Washington, Seattle, Washington.

Moses Galukande (M)

Department of Surgery, School of Medicine, Makerere University, Kampala, Uganda.

Jimmy Okello (J)

Department of Radiology, Mulago Hospital, Kampala, Uganda.

Gertrude Nakigudde (G)

Uganda Women's Cancer Support Organization, Kampala, Uganda.

Noleb Mugisha (N)

Uganda Cancer Institute, Kampala, Uganda.
Community Prevention and Screening, Ugandan Cancer Institute, Kampala, Uganda.

Zeridah Muyinda (Z)

Department of Radiology, Mulago Hospital, Kampala, Uganda.

Benjamin O Anderson (BO)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Global Health, University of Washington, Seattle, Washington.
Department of Surgery, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington.

Catherine Duggan (C)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH